Skip to main navigation
Skip to search
Skip to main content
Experts@Minnesota Home
Search content at Experts@Minnesota
Home
Profiles
Research units
University Assets
Projects and Grants
Research output
Datasets
Press/Media
Activities
Fellowships, Honors, and Prizes
Impacts
Tuberous sclerosis and fulminant lupus in a young woman
Namrata Singh
, Mark Birkenbach
, Tiffany Caza
, Andras Perl
, Philip L. Cohen
Research output
:
Contribution to journal
›
Article
›
peer-review
32
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Tuberous sclerosis and fulminant lupus in a young woman'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Lupus
100%
Young Women
100%
Systemic Lupus Erythematosus
100%
Tuberous Sclerosis
100%
Mammalian Target of Rapamycin Signaling Pathway
66%
Immune System
33%
Lung
33%
Mammalian Target of Rapamycin (mTOR)
33%
Kidney
33%
Tuberous Sclerosis Complex
33%
Dysregulation
33%
Plasmapheresis
33%
Rare Diseases
33%
Constitutive Activation
33%
Nephritis
33%
Nervous System
33%
Autosomal Dominant Disorder
33%
Lower Extremity Edema
33%
High-dose Steroids
33%
High-dose Cyclophosphamide
33%
TSC1
33%
Massive Proteinuria
33%
Tuberin
33%
TSC mutations
33%
Hamartin
33%
Lupus Glomerulonephritis
33%
Severe Systemic Lupus Erythematosus
33%
Medicine and Dentistry
Fulminant
100%
Mechanistic Target of Rapamycin
100%
Tuberous Sclerosis
100%
Systemic Lupus Erythematosus
100%
Lupus Erythematosus
100%
Lupus Nephritis
66%
Lung
33%
Drug Megadose
33%
Cyclophosphamide
33%
Proteinuria
33%
Edema
33%
Nervous System
33%
Plasmapheresis
33%
Rare Disease
33%
Immune System
33%
Hamartin
33%
Tuberin
33%
Autosomal Dominant Disorder
33%
Steroids
33%
Pharmacology, Toxicology and Pharmaceutical Science
Mammalian Target of Rapamycin
100%
Systemic Lupus Erythematosus
100%
Tuberous Sclerosis
100%
Lupus Erythematosus Nephritis
66%
Steroids
33%
Cyclophosphamide
33%
Rare Disease
33%
Tuberin
33%
Hamartin
33%
Proteinuria
33%
Edema
33%
Autosomal Dominant Disorder
33%